National Graphite Corporation (NGRC)

Overview

National Graphite Corp., initially established as Lucky Boy Silver Corporation in 2006, underwent a significant transition to its current identity in May 2012. Headquartered in Duesseldorf, Germany, the company operates through its subsidiary, Biotech Development Corp., positioning itself within the biopharmaceutical sector as a risk/cost-sharing enterprise. The main focus of National Graphite Corp. is to collaborate with clinical stage companies. These partnerships are centered on the development of new biological entities or therapeutically innovative platforms aimed at addressing a range of diseases, including rare conditions and diseases that currently have unmet medical needs. The strategic shift towards biopharmaceutical endeavors marks a notable pivot from its original operations in the mining sector, reflecting an adaptive strategy in the evolving business landscape.

Products and Services

National Graphite Corp.’s portfolio is primarily focused on the development and commercialization of novel biopharmaceuticals, with a significant collaboration highlighting its innovative drive:

• ELAFIN Drug Candidate: A prime example of National Graphite Corp.’s commitment to addressing unmet medical needs through biopharmaceutical innovation. ELAFIN is an experimental therapeutic agent that represents a human identic protein under development for the treatment of postoperative inflammatory complications. The promising potential of ELAFIN stems from its target specificity and novel approach in managing post-surgical inflammatory responses, which are critical areas of need in medical treatment. To expedite the development and ensure the commercial viability of this drug candidate, National Graphite Corp. has entered into a collaboration agreement with Proteo Inc., leveraging mutual strengths and resources for achieving their shared objectives.